NASDAQ:UPB

Upstream Bio Q2 2025 Earnings Results & Report

Upstream Bio logo
$2.00 -0.08 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 +0.02 (+0.75%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upstream Bio missed analyst earnings expectations but beat on revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$0.74 versus the -$0.61 consensus estimate, while revenue of $940 thousand topped the $317 thousand estimate by $623 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Upstream Bio EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.61
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Upstream Bio Revenue Results

Actual Revenue
$940 thousand
Expected Revenue
$317 thousand
Beat/Miss
Beat by +$623.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Q2 2025 Earnings FAQ

Upstream Bio (NASDAQ:UPB) reported earnings of -$0.74 per share for Q2 2025, missing the consensus estimate of -$0.61. The report was announced on Wednesday, August 6, 2025.

Upstream Bio reported revenue of $940 thousand for Q2 2025, against a consensus estimate of $317 thousand.

Upstream Bio Earnings Headlines

HC Wainwright Increases Earnings Estimates for Upstream Bio
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB) is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses.

Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.

The company’s work is focused on drug development and clinical research; it does not have a marketed product portfolio.

View Upstream Bio Profile